Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414–4422

Article  PubMed  Google Scholar 

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172

Article  PubMed  Google Scholar 

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D et al (2021) Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 23:149

Article  PubMed  PubMed Central  Google Scholar 

Hassett MJ, O’Malley AJ, Pakes JR, Newhouse JP, Earle CC (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. JNCI: J Natl Cancer Inst 98(16):1108–1117

Article  PubMed  Google Scholar 

Azim HA, de Azambuja E, Colozza M, Bines J, Piccart MJ (2011) Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 22(9):1939–1947

Article  PubMed  Google Scholar 

Hennigs A, Biehl H, Rauch G, Golatta M, Tabatabai P, Domschke C et al (2016) Change of patient-reported aesthetic outcome over time and identification of factors characterizing poor aesthetic outcome after breast-conserving therapy: long-term results of a prospective cohort study. Ann Surg Oncol 23(5):1744–1751

Article  PubMed  Google Scholar 

Dahlbäck C, Ullmark JH, Rehn M, Ringberg A, Manjer J (2017) Aesthetic result after breast-conserving therapy is associated with quality of life several years after treatment. Swedish women evaluated with BCCT.core and BREAST-Q™. Breast Cancer Res Treat 164(3):679–687

Article  PubMed  PubMed Central  Google Scholar 

Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S et al (2022) Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol 40(16):1816–1837

Article  CAS  PubMed  Google Scholar 

Candido Dos Reis FJ, Wishart GC, Dicks EM, Greenberg D, Rashbass J, Schmidt MK et al (2017) An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast cancer Res: BCR 19(1):58

Article  PubMed  PubMed Central  Google Scholar 

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, Wessels LF et al (2013) Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat 140(1):63–71

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. (2017) Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(4):290–303

Li S, Zhang Y, Zhang P, Xue S, Chen Y, Sun L, Yang R (2022) Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: a meta-analysis. Breast 66:97–109

Article  PubMed  PubMed Central  Google Scholar 

Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J et al (2021) The immunology of hormone receptor positive breast cancer. Front Immunol. https://doi.org/10.3389/fimmu.2021.674192

Article  PubMed  PubMed Central  Google Scholar 

Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK et al (2022) A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol 149:110220

Article  PubMed  Google Scholar 

(IKNL) IkN. Landelijke richtlijn Borstkanker 2020 [Available from: https://richtlijnendatabase.nl

Janssen LM, Janse MHA, Penning de Vries BBL, van der Velden BHM, Wolters-van der Ben EJM, van den Bosch SM et al (2024) Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer. NPJ Breast Cancer 10(1):10

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs working group 2014. Ann Oncol 26(2):259–271

Article  CAS  PubMed  Google Scholar 

Center MAC. Residual Cancer Burden Calculator [cited 2018. Available from: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3

Alderliesten T, Schlief A, Peterse J, Loo C, Teertstra H, Muller S, Gilhuijs K (2007) Validation of semiautomatic measurement of the extent of breast tumors using contrast-enhanced magnetic resonance imaging. Invest Radiol 42(1):42–49

Article  PubMed  Google Scholar 

Janse MHA, Janssen LM, van der Velden BHM, Moman MR, Wolters-van der Ben EJM, Kock MCJM et al (2023) Deep learning-based segmentation of locally advanced breast cancer on MRI in relation to residual cancer burden: a multi-institutional cohort study. J Magn Reson Imaging 58(6):1739–1749

Article  PubMed  Google Scholar 

Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25(15):2127–2132

Article  PubMed  Google Scholar 

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE et al (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19(1):40–50

Article  PubMed  Google Scholar 

van Hemert AKE, van Duijnhoven FH, van Loevezijn AA, Loo CE, Wiersma T, Groen EJ, Peeters M (2023) Biopsy-guided pathological response assessment in breast cancer is insufficient: additional pathology findings of the MICRA trial. Ann Surg Oncol 30:4682

Article  PubMed  PubMed Central  Google Scholar 

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H et al (2012) Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 132(3):793–805

Article  CAS  PubMed  Google Scholar 

Hwang HW, Jung H, Hyeon J, Park YH, Ahn JS, Im YH et al (2019) A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Res Treat 173(2):255–266

Article  CAS  PubMed  Google Scholar 

Russo L, Maltese A, Betancourt L, Romero G, Cialoni D, De la Fuente L et al (2019) Locally advanced breast cancer: tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy. Eur J Surg Oncol 45(6):963–968

Article  PubMed  Google Scholar 

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol 31(7):860–867

Article  CAS  PubMed  Google Scholar 

Miyashita M, Sasano H, Tamaki K, Chan M, Hirakawa H, Suzuki A et al (2014) Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 148(3):525–534

Article  CAS  PubMed  Google Scholar 

Elmahs A, Mohamed G, Salem M, Omar D, Helal AM, Soliman N (2022) The impact of tumor infiltrating lymphocytes densities and Ki67 index on residual breast cancer burden following neoadjuvant chemotherapy. Int J Breast Cancer 2022:2597889

Article  PubMed  PubMed Central  Google Scholar 

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810–821

Article  CAS  PubMed  Google Scholar 

Loi S, Curigliano G, Salgado RF, Romero Diaz RI, Delaloge S, Rojas C et al (2023) LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC). Ann Oncol 34:S1259–S1260

Article  Google Scholar 

Cardoso F, McArthur HL, Schmid P, Cortés J, Harbeck N, Telli ML et al (2023) LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2− breast cancer. Ann Oncol 34:S1260–S1261

Article